Streetbeat News

Products Services

BGNE

Luye has announced that its Goserelin Microspheres for injection has received approval from China's National Medical Products Administration for treating breast cancer. The company is partnering with Beigene Ltd to commercialize the product in mainland China.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 12:50 pm

BLRX

CRNX

NBY

Crinetics' Paltusotine achieved all endpoints in Phase 3 study, potentially boosting CRNX's stock. NovaBay Pharmaceuticals announced an agreement with BioStem Technologies to commercialize Avenova® Allograft, which could positively impact NBY's stock. BioLineRx received FDA approval for APHEXDA™ in combination with Filgrastim for patients with Multiple Myeloma, which may increase BLRX's stock.

Portfolio Pulse from ryanfaloona@benzinga.com

September 11, 2023 | 12:48 pm

CASA

USM

UScellular has chosen Casa Systems for the provision of self-install 5G outdoor fixed wireless access devices. The financial terms of the deal were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 12:37 pm

DAWN

Day One Biopharmaceuticals has announced updated data for its FIREFLY-1 study of Tovorafenib, a treatment for relapsed or progressive pediatric low-grade glioma. The data shows an overall response rate of over 50%, with a median duration of treatment of 15.8 months.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 12:36 pm

DAWN

Day One Biopharmaceuticals has submitted a rolling New Drug Application (NDA) to the FDA for Tovorafenib, a treatment for relapsed or progressive pediatric low-grade glioma. The company expects the FDA to file the application by mid-November.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 12:35 pm

NBIX

Neurocrine Biosciences has announced the initiation of a Phase 1 clinical study evaluating the effects of NBI-1117570 in healthy adults.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 12:34 pm

NFTG

NFT Gaming Company has launched its new game 'Space Striker AI' for Android and iOS platforms.

Portfolio Pulse from Bill Haddad

September 11, 2023 | 12:33 pm

PRFX

Painreform has announced plans to commence the second part of its Phase 3 clinical trial for PRF-110 in patients undergoing bunionectomy surgery. The trial is expected to start in mid-Q4 2023, with results anticipated in mid-2024. This follows a review of the Drug Master File by the FDA.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 12:32 pm

BLRX

The FDA has approved BioLineRx's Aphexda plus filgrastim for use in mobilizing hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in multiple myeloma patients. This has led to an increase in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 12:32 pm

NBY

Novabay Pharmaceuticals has granted Biostem Technologies the right to commercialize Amniotic Tissue Allograft, a product intended for use as a protective covering during the repair of ocular surfaces. This has led to a rise in Novabay's share prices.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 12:24 pm